UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2020
Commission File Number:001-38281
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This Report on Form6-K and Exhibit 99.1 to this Report on Form6-K shall be deemed to be incorporated by reference into the registration statement on FormF-3 (FileNo. 333-232669) and registration statements on FormS-8 (File Nos.333-222673 and333-232670), of ERYTECH Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
INFORMATION CONTAINED IN THIS REPORT ON FORM6-K
ERYTECH Pharma S.A. today announced its unaudited financial results for the nine months ended September 30, 2019. Its financial report, including its condensed consolidated financial statements as of September 30, 2019, is attached to this Report on Form6-K as Exhibit 99.1.
EXHIBITS
Exhibit | Description | |
99.1 | Financial Report, including the Company’s condensed consolidated financial statements as of September 30, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A. | ||||||
Date: February 6, 2020 | By: | /s/ Eric Soyer | ||||
Name Eric Soyer | ||||||
Title: Chief Financial Officer and Chief Operating Officer |